000 06201cam a2200409Ii 4500
001 96006
003 ES-MaUEC
005 20230102112733.0
006 m o d
007 cr cnu|||unuuu
008 170517s2017 si a o 000 0 eng d
020 _a9789811039782
_q(electronic bk.)
020 _a981103978X
_q(electronic bk.)
020 _z9789811039775
_q(print)
020 _z9811039771
040 _aN$T
_cN$T
_dEBLCP
_dGW5XE
_dN$T
_dYDX
_dOCLCF
_dUAB
_dESU
_dAZU
_dUPM
_dIOG
_dCOO
_dOCLCQ
_dMERER
_dOCLCQ
_dU3W
_dES-MaUEC
_bspa
050 4 _aRC280.S8
_b2017 EB
245 0 0 _aPersonalized management of gastric cancer :
_btranslational and precision medicine
_cJia Wei, Baorui Liu, editors.
264 1 _aSingapore
_bSpringer International Publishing
_c2017
300 _a1 recurso en línea (viii, 227 páginas)
_bilustraciones (algunas a color)
336 _aTexto
_btxt
_2rdacontent
337 _aelectrónico
_bc
_2rdamedia
338 _arecurso electrónico
_bcr
_2rdacarrier
347 _atext file
_bPDF
505 0 _aPreface; Contents; Part I: Personalized Therapy in Gastric Cancer; 1: Molecular Pathology of Heredity Gastric Cancer; 1.1 Introduction; 1.2 Hereditary Diffuse Gastric Cancer; 1.3 Gastric Adenocarcinoma and Proximal Polyposis Syndrome; 1.4 Familial Intestinal Gastric Cancer; 1.5 Lynch Syndrome; 1.6 Familial Adenomatous Polyposis/MUTYH- Associated Polyposis/Attenuated Familial Adenomatous Polyposis; 1.7 Peutz-Jeghers Syndrome; 1.8 Juvenile Polyposis Syndrome; 1.9 Li-Fraumeni Syndrome; 1.10 BRCA1 and BRCA2 Hereditary Breast and Ovarian Cancer; 1.11 Cowden Syndrome; References.
505 8 _a2: Genetics and Molecular Signature of Gastric Cancer2.1 Introduction; 2.2 The Genomic Susceptibility of Gastric Cancer; 2.3 SNPs in Candidate Genes; 2.3.1 Mucins; 2.4 Inflammatory Cytokines and Immune Response Genes; 2.5 Other Genetic Variants; 2.6 Susceptibility Regions Identified by GWAS; 2.6.1 1q22; 2.6.2 5p13.1; 2.6.3 8q24.3; 2.6.4 10q23.33; 2.7 Other Regions; 2.8 Molecular Signature of Gastric Cancer; 2.8.1 Microsatellite Instability and Chromosomal Instability in Gastric Cancer; 2.9 Molecular Subtyping of GC; 2.10 "Driver" Alterations of Gastric Cancer; References.
505 8 _a3.5.1 Prognostic Potentials of CTC in Gastric Cancer3.5.2 Genetic Analysis of CTC; 3.5.2.1 Detection of Tumor-Associated Amplification in CTC; 3.5.2.2 Genomic Tumor Mutation Profile Assessed in CTC; 3.5.2.3 Detection of Tumor-Associated mRNA in CTC; 3.6 Perspectives; References; 4: Customized Chemotherapy in Advanced Gastric Cancer; 4.1 Introduction; 4.2 Chemotherapy in Advanced Gastric Cancer; 4.3 Customized Chemotherapy in Advanced Gastric Cancer; 4.3.1 Platinum; 4.3.2 5-Fluorouracil (5-FU)/Capecitabine/S-1; 4.3.3 Taxanes; 4.3.4 Irinotecan(CPT-11); 4.3.5 Pemetrexed.
505 8 _a3: Circulating Tumor Cells in Gastric Cancer3.1 Introduction; 3.2 Biology of Circulating Tumor Cells; 3.3 Detection of Circulating Tumor Cells; 3.3.1 Enrichment of Circulating Tumor Cells; 3.3.1.1 Enrichment by Density Gradient Centrifugation; 3.3.1.2 Immune-Magnetic Separation; 3.3.1.3 Size-Based Isolation; 3.3.1.4 CTC-Chip; 3.3.1.5 In Vivo Isolation; 3.3.2 Identification and Characterization of CTCs; 3.4 Ex Vivo and In Vivo Culture of CTCs; 3.4.1 Ex Vivo Culture of CTCs; 3.4.2 In Vivo Culture of CTC; 3.5 Clinical Implications of Circulating Tumor Cells.
505 8 _a4.3.6 Other Regimens4.3.7 Markers for Toxicity; References; 5: Targeted Therapy in Advanced Gastric Cancer; 5.1 Novel Comprehensive Classification of Gastric Cancer; 5.2 Targeting the Driver Oncogenes of Tumor Cells; 5.2.1 HER2; 5.2.2 EGFR; 5.2.3 HGF Pathway; 5.2.4 FGFR2; 5.2.5 mTOR; 5.2.6 Cell Cycle; 5.3 Targeting Angiogenesis; 5.3.1 Anti-VEGF Antibody (Bevacizumab); 5.3.2 Anti-VEGFR-2 Antibody (Ramucirumab); 5.3.3 Anti-VEGFR-2 Receptor Tyrosine Kinases (Apatinib); 5.3.4 Angiogenic Receptor Tyrosine Kinases (Sunitinib, Sorafenib, Etc.); 5.4 Immune-Checkpoint Blockade.
520 3 _aThis book offers essential information on basic and translational research in gastric cancer, while also illustrating potential opportunities for its application in clinical practice. Gastric cancer is the fourth-most-common cancer globally and the second-leading cause of cancer deaths. It is known to be a heterogeneous disease with varied responses to "one-size-fits-all" treatments. Expanding our knowledge of cancer cell genetics may help us to explore more effective treatments in gastric cancer. The research on molecular mechanisms and its clinical applications, both presented here, will help readers gain an in-depth understanding of gastric cancer and its effective treatment. The book's four sections cover personalized medicine, precise regional therapy, immunotherapy and nanomedicine in gastric cancer. Each part presents the state of art, recent advances and the authors' experiences. Moreover, several interesting cases are described to demonstrate how gastric cancer patients benefit from translational research. This informative and attractively presented book on precision treatment in gastric cancer, including experimental findings and clinical treatment options, offers a valuable resource for oncologists and graduate students working in the field of gastric cancer. Jia Wei, MD, PhD, is an associate professor at Nanjing University and the vice director of Clinical Cancer Institute of Nanjing University. She is now working as an oncologist in the Comprehensive Cancer Center, Affiliated Drum Tower Hospital to Medical School of Nanjing University. Baorui Liu, MD, PhD, is a professor at Nanjing University and director of the Clinical Cancer Institute of Nanjing University. He is also the director of the Comprehensive Cancer Center of Drum Tower Hospital.
650 7 _aEstómago
_xCáncer
_2embne
_0(OCoLC)fst01133772
_0
_9670603
700 1 _aLiu, Baorui,
_eeditor literario
700 1 _aWei, Jia,
_eeditor literario
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-981-10-3978-2
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
988 _aSpringer_Medicine_2017
998 _b02/2018
_dz
_e-
_zSI
999 _c96006
_d96006
_x1